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Abstract
Background: Hypertension is prevalent in Singapore and is a major risk factor for cardiovascular morbidity and mortality and
increased health care costs. Strategies to lower blood pressure include lifestyle modifications and home blood pressure monitoring.
Nonetheless, adherence to home blood pressure monitoring remains low. This protocol details an algorithm for remote management
of primary care patients with hypertension.
Objective: The objective of this study was to determine whether wireless home blood pressure monitoring with or without
financial incentives is more effective at reducing systolic blood pressure than nonwireless home blood pressure monitoring (usual
care).
Methods: This study was designed as a randomized controlled open-label superiority study. A sample size of 224 was required
to detect differences of 10 mmHg in average systolic blood pressure. Participants were to be randomized, in the ratio of 2:3:3,
into 1 of 3 parallel study arms :(1) usual care, (2) wireless home blood pressure monitoring, and (3) wireless home blood pressure
monitoring with financial incentives. The primary outcome was the mean change in systolic blood pressure at month 6. The
secondary outcomes were the mean reduction in diastolic blood pressure, cost of financial incentives, time taken for the intervention,
adherence to home blood pressure monitoring, effectiveness of the framing of financial incentives in decreasing nonadherence
to blood pressure self-monitoring and the adherence to antihypertensive medication at month 6.
Results: This study was approved by SingHealth Centralised Institutional Review Board and registered. Between January 24,
2018 and July 10, 2018, 42 participants (18.75% of the required sample size) were enrolled, and 33 participants completed the
month 6 assessment by January 31, 2019.
Conclusions: Due to unforeseen events, the study was stopped prematurely; therefore, no results are available. Depending on
the blood pressure information received from the patients, the algorithm can trigger immediate blood pressure advice (eg, Accident
and Emergency department visit advice for extremely high blood pressure), weekly feedback on blood pressure monitoring,
medication titration, or skipping of routine follow-ups. The inclusion of financial incentives framed as health capital provides a
novel idea on how to promote adherence to remote monitoring, and ultimately, improve chronic disease management.
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Introduction
Hypertension is prevalent in Singapore, affecting 23.5% of
adults between 18 to 69 years of age [1]. It is a major risk factor
for cardiovascular morbidity and mortality [2,3] and is
associated with significant health care cost [4,5]. The goal of
hypertension management is to lower blood pressure to healthy
ranges through lifestyle modifications such as restricting salt
and alcohol intake, eating a healthy diet, losing weight, engaging
in regular exercise, quitting smoking, and taking
antihypertensive medication(s) [6].
For patients whose blood pressure remains high, doctors
routinely recommend home blood pressure monitoring for better
blood pressure control. Home blood pressure monitoring allows
the doctor to monitor response to treatment, detect white-coat
hypertension, and predict cardiovascular risk [7,8]. Nonetheless,
adherence to home blood pressure monitoring and medication(s)
remains low [9]. Even when patients adhere to home monitoring,
the readings are not reviewed by the doctor until the patient’s
subsequent in-person visit, which may be several weeks later.
To address this, telemonitoring [10-14] can be employed as it
allows for health care providers to monitor and intervene [15],
to increase adherence to blood pressure monitoring [16], or
titrate blood pressure medication [17] as needed, potentially
without requiring an in-person visit [18]. However, systematic
reviews [19,20] on telemonitoring reveal that it produces only
modest improvements, which suggests that other features are
needed [21-25]. For example, features such as automatic
reminders [26,27], weekly feedback [28], or clinical
interventions in response to concerning blood pressure trends
(eg, medication titration), and financial incentives can be
considered.
Behavioral economic theory suggests that the high rates of
nonadherence to lifestyle modifications result, at least in part,
from patients not perceiving a clear cause and effect relationship
between greater adherence and reduced likelihood of adverse
health consequences (eg, cardiovascular disease and premature
death) [29,30]. The financial cost, such as the cost of
medication(s), and nonfinancial costs, such as eating healthy,
exercising, medication adherence, and blood pressure monitoring
efforts, occur today, whereas the benefits, such as reduced risk
for major cardiovascular events, often appear distant and
uncertain. As a result, and because many individuals with
hypertension feel perfectly healthy, they do not internalize the
costs of nonadherence until it is too late. This theory suggests
that a strategy to improve adherence is by providing a short-term
financial incentive—an immediate benefit to offset the costs
associated with the behavior change. Similar economic
incentives have been used successfully in several
adherence-enhancing interventions [31-34].
Therefore, this study aimed to leverage the potential of wireless
and mobile technology and introduce financial incentives to
improve the effectiveness of home blood pressure monitoring.
The primary objective of this study was to determine whether
wireless home blood pressure monitoring, with or without
financial incentives, is more effective at reducing systolic blood
pressure than nonwireless home blood pressure monitoring that
relies on patient self-report (usual care). The secondary
objectives were to improve adherence to blood pressure
monitoring and antihypertensive medication(s).
Methods
Trial Design
The study was designed as a randomized controlled open-label
superiority study with 3 parallel arms. Patients with hypertension
who were on antihypertensive medication were randomized to
(1) usual care, (2) wireless home blood pressure monitoring
only, and (3) wireless home blood pressure monitoring with
financial incentives arms, in a ratio of 2:3:3. Participants were
randomly stratified based on whether they had diabetes mellitus
(diabetes) and by clinic. The study intervention was to last 6
months. This protocol conforms to CONSORT (Consolidated
Standards of Reporting Trials [35]) guidelines; the checklist
can be found in Multimedia Appendix 1.
Study Setting and Eligibility Criteria
Patients were recruited from Bedok and Marine Parade
Polyclinics (SingHealth Polyclinics) in Singapore. Bedok and
Marine Parade Polyclinics provide primary health care services
to the eastern and southern region of Singapore. Hypertension
management is one of the key services provided. Participant
eligibility was based on the inclusion and exclusion criteria
(Textbox 1).
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Textbox 1. Inclusion and exclusion criteria.
Inclusion criteria
Participants had to fulfil all of the following:
• Diagnosed hypertension and on at least 1 antihypertensive medication
• Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg for patients without diabetes (systolic blood pressure ≥140 mmHg
or diastolic blood pressure ≥85 mmHg for patients with diabetes), which was verified by the average of the last 2 of 3 blood pressure readings
taken on the day of the screening visit at 3-minute intervals [36] (model: HEM-7130, Omron)
• Age from 21 to 70 years of age
• Singapore citizens or permanent residents
• Able to converse in English
• Has a compatible smartphone (iOS: versions 8.0 and higher, Android: versions 5.0 and higher) with data plan or regular Wi-Fi access
• Ability to perform self-monitoring of blood pressure as assessed by the clinical research coordinator
• Expecting to be a patient of Bedok or Marine Parade Polyclinics for the duration of the trial
Exclusion criteria
Patients with any of the following were not enrolled:
• Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg which was verified by the average of the last 2 of 3 blood pressure
readings taken on the day of the screening visit at 3-minute intervals (model: HEM-7130, Omron)
• Started on angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers within the last 3 months
• Clinically unstable heart failure
• Advanced kidney disease (estimated glomerular filtration rate <30 mL/minute CKD-EPI Creatinine formula [37]
• Acute kidney injury (ie, increase in serum creatinine ≥50% from baseline within the past week
• Confirmed glomerulonephritis
• Severe or overt macro albuminuria (urine albumin-to-creatinine ratio >30 mg/mmol or protein-to-creatinine ratio >0.5)
• Known liver disease (eg, liver cirrhosis)
• Atrial fibrillation
• On warfarin or anticoagulants (eg, novel oral anticoagulants)
• Underwent double mastectomy
• Pregnant
• Known allergy to epoxy resin
• Newly referred to specialist outpatient clinics or upon follow-up for complications related to hypertension
• Discharged from hospital within the last 3 months for complications related to hypertension
• Any other major debilitating disease or mental illness that precludes validity of informed consent or would result in the patient being unable to
take their blood pressure independently
• Living in a household where another member has been recruited into the trial
Participant Recruitment, Timeline, and Study Arms
Overview
Participants were recruited via posters and referrals at Bedok
and Marine Parade Polyclinics. A screening visit was arranged
during which the study’s purpose was explained and the screener
administered. For eligible patients, the clinical research
coordinator went through the participant information sheet, and
if the patient agreed to participate, obtained informed consent
(Multimedia Appendix 2).
Blood pressure was assessed at baseline and at month 6.
Participants wore an ambulatory blood pressure monitor (model
7100, Welch Allyn) for 12 hours while awake (eg, 9 AM-9 PM).
A period of 12 hours instead of 24 hours was chosen to reduce
participant burden [38]. A diary was also given to participants
to record antihypertensive medication adherence and physical
activity (Multimedia Appendix 3, Figure S1). Participants were
also issued a home blood pressure monitor and advised to
monitor their blood pressure 3 times per week during the study.
Medication Tracker (eCAP) was also issued, and participants
were advised to store their most frequently prescribed
antihypertensive medication in it. A demonstration of the study
devices was given. The baseline questionnaire was administered
(in paper format) at Bedok and Marine Parade Polyclinics, and
the participant’s responsibilities and adherence goals explained.
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The study intervention began on the Monday following the valid
baseline ambulatory blood pressure monitoring test (defined as
having at least 70% of successful readings [39]). Participants
also completed questionnaires at the 6-month assessment.
Multimedia Appendix 4 contains the study timeline.
Arm 1: Usual Care
SingHealth Polyclinics have a structured framework for
hypertension management. Patients who are newly diagnosed
with hypertension would be prescribed antihypertensive
medication if deemed necessary by the doctor. All patients are
subsequently referred to a nurse who would provide further
information on hypertension and come up with a lifestyle
modification plan with the patient. Patients are then followed
up by the doctors and nurses at 3- to 4-month intervals (or more),
based on their blood pressure trend. Further education is given
at these visits as needed. Patients with good blood pressure
control can teleconsult with a trained nurse, alternating with
in-person doctor's consultation at up to 6-month intervals if they
monitor their blood pressure at home. There are in-house
pharmacists who assist patients in understanding their
medication doses and regimens. Regular blood tests (ie,
electrolytes, renal function, lipids, and glucose) are also carried
out annually to monitor the patient’s response to treatment and
to detect any disease progression and complications. Patients
with evidence of disease progression and complications would
be closely monitored and referred to the appropriate specialists
if required.
Participants in the usual care arm were advised to use their
existing blood pressure monitor. Participants who did not have
a home blood pressure monitor were given a blood pressure
monitor (HEM 7130, Omron). In order to properly identify the
effect of contingent financial incentives, all participants received
a participant leaflet (Textbox 2).
The clinical research coordinator also provided advice on
self-management and education on how to interpret blood
pressure readings according to a standard self-monitoring
guideline (Multimedia Appendix 5). The self-monitoring
instructions were adapted from the guidelines of the Healthy
Singapore website, a website by the Singapore Ministry of
Health which was discontinued in September 2016. Elevated
blood pressure was defined as clinic-measured systolic blood
pressure 140 mmHg or diastolic blood pressure 90 mmHg.
Published home-based monitoring protocols however, state that
for home blood pressure monitoring, systolic blood pressure
≥135 mmHg or diastolic blood pressure ≥85 mmHg is indicative
of elevated blood pressure [40,41]. In addition, SingHealth
Polyclinics guidelines recommend home blood pressure
monitoring targets of <135/80 mmHg for patients with diabetes,
and <135/85 mmHg for those without diabetes. We therefore
worked with the SingHealth Polyclinics Telehealth Team to
fine-tune the blood pressure cut-offs for the various categories
in order to have the same blood pressure cut-offs as the
intervention (Table 1).
Participants in Arm 1 recorded their blood pressure readings
on the SingHealth Polyclinics home blood pressure charting
form (in paper format) as part of usual care. For monitoring
adherence to hypertensive medicines, an eCAP (Information
Mediary Corp) was used. The eCAP device passively recorded
the dates and times the bottle was opened; these data are stored
in the memory via an radiofrequency identification tag. Data
were extracted by scanning the eCAP device on a reader
(CertiScan desktop). Participants were assessed for adherence
within specified time windows (eg, if a participant’s specified
timing is 5 AM to 11 AM and 5 PM to 11 PM, a reading had
to be logged within both windows for the participant to be
considered adherent for that day).
Textbox 2. Participant leaflet.
Aim to achieve blood pressure readings in the normal range
Measure your blood pressure on at least 3 days each week
Recommendations:
1. It is best to measure your blood pressure in the morning, before you take your medication, coffee, tea, smoke or exercise. Please sit for at least
5 minutes before measuring your blood pressure.
2. It is also recommended that you measure your blood pressure before you sleep at night.
Get active
Eat better. Reduce your salt intake
Take your medication as prescribed by your doctor.
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Table 1. Blood pressure classification.
Extremely highVery highSlightly highNormalLow normalVery lowDiabetes status
No diabetes
≥180160-179135-159100-13490-99<90Systolic blood pressure (mmHg)
≥110100-10985-9960-8450-59<50Diastolic blood pressure (mmHg)
Diabetes
≥180160-179135-159100-13490-99<90Systolic blood pressure (mmHg)
≥110100-10980-9960-7950-59<50Diastolic blood pressure (mmHg)
Arm 2: Wireless Home Blood Pressure Monitoring
System
Participants in Arm 2 used an asynchronous telehealth system
that consisted of a wireless home blood pressure monitor and
app (Figure 1). The study app comprised 3 parts: (1) instant
home blood pressure monitoring advice, (2) weekly home blood
pressure monitoring adherence feedback, and (3) 28-day
continuous home blood pressure monitoring assessment.
The participants monitored their blood pressure using a wireless
upper arm blood pressure monitor (iHealth KN-550BT [42]).
The blood pressure monitor transmitted the readings via
Bluetooth and internet to a smartphone app on the participants’
smartphones. Participants received training from the clinical
research coordinator on how to use the device and to upload
their blood pressure readings. This smartphone app was available
at no charge to study participants. Data were automatically sent
to secure participant accounts, then pushed to a secure study
app. The study app then sent feedback SMS text messages to
the participants and automatically triggered interventions from
the polyclinics depending on the blood pressure readings (Table
2).
Figure 1. Wireless home blood pressure monitoring system. BP: blood pressure; CRC: Clinical Research Coordinator; WiFHy: Wireless Monitoring
and Financial Incentives for Uncontrolled Hypertension.
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Table 2. Blood pressure–related procedures.
DescriptionPart
Each blood pressure reading was classified in the order of most abnormal to normal (ie ex-
tremely high, very high, slightly high, very low, low normal and normal) and displayed on
the study website. Based on the blood pressure classification, the participant received SMS
self-management advice. A colour coded protocol (Red protocol)a was activated for very low
and extremely high blood pressure readings.
Part 1: Instant home blood pressure monitoring advice
(Multimedia Appendix 6)
Participants received automated praise, encouragement, or reminder SMS messages on the
Monday of the following week at 8 AM throughout the intervention, with content that were
dependent on their adherence to home blood pressure monitoring the week prior.
Part 2: Weekly home blood pressure monitoring adher-
ence feedback (Multimedia Appendix 7)
The average of blood pressure readings over the past 28 days was calculated daily based on
readings over the preceding 28 days. It was categorized in the order of most abnormal to
normal and color codeda. The triggering of interventions based on the average blood pressure
in the past 28 days is in line with previous studies that recommend using the average of a series
of measurements for clinical decisions [43]. The 28-day continuous home blood pressure
monitoring assessment occurred when the system detected a minimum of 8 blood pressure
readings in the past 28 days.
Part 3: 28-day continuous home blood pressure monitor-
ing assessment (Multimedia Appendix 8)
aColor-coded protocols (Multimedia Appendix 8)—red: for very low and extremely high blood pressure; black: for very low or extremely high average
blood pressure; gray: for low normal average blood pressure; green: for average blood pressure within the normal range just before scheduled clinic
visit (participants were eligible to skip their upcoming clinic visit on approval of a doctor after review of the participant’s clinical history and verification
of the participant’s current well-being by the clinical research coordinator); pink: for slightly high or very high average blood pressure (remote drug
titration for participants on selected drugs); yellow: no readings for the past 28 days (the clinical research coordinator contacted the participant to
determine the reason).
Remote Titration (Arm 2 and 3 Participants Only)
To be clinically more responsive to uncontrolled blood pressure,
remote titration is integrated in this intervention as per the Joint
National Committee 8 [44] recommendation to increase the
dose of an initial drug if goal blood pressure is not reached
within 1 month of treatment. This protocol for drug titration is
based on an unpublished pilot program at Pasir Ris Polyclinic.
Participants were eligible for remote titration if they were
randomized to Arms 2 and 3 and prescribed (1) nifedipine LA
≤30 mg/day, (2) amlodipine ≤7.5 mg/day, (3) atenolol ≤75 mg
every morning or (4) bisoprolol ≤7.5 mg every morning at
baseline. For participants who were on more than 1 drug, the
study doctor determined the drug to be titrated based on the
drug selection workflow (Multimedia Appendix 8, Figure S4)
and gave instructions on the dose increase to the participant.
The participant was to increase the dose only if contacted by
the clinical research coordinator to do so during the intervention.
The doctor’s instructions were also written in an individualized
leaflet (Remote Titration Action Plan–Patient Information
Leaflet; Multimedia Appendix 8, Figure A8.4.1.2) and given
to the participant for reference. The clinical research coordinator
also tagged the drug to be titrated and reinforced the doctor’s
advice. Participants were prescribed the full duration of the
antihypertensive drugs until their next scheduled clinic visit.
The drugs selected for remote titration were calcium channel
blockers and beta blockers as these do not require monitoring
of electrolytes.
On each working day, the clinical research coordinator logged-in
to the study website, monitored the dashboard for flags and
intervened accordingly. The clinical research coordinator
unflagged the flag once the intervention had been carried out.
Study participants had doctor consultations at month 3 and at
month 6 during the intervention period. For Arm 1 participants,
the clinical research coordinator met with them prior to their
doctor consultation and made a copy of their blood pressure
readings for record. For Arm 2 and 3 participants, the clinical
research coordinator passed them the blood pressure readings
captured by the wireless monitoring system on the day of the
doctor consultation for review by the doctor; except in cases
where the visit was skipped due to good blood pressure control
(green protocol).
Arm 3: Wireless Home Blood Pressure Monitoring
System With Incentives
Participants in this arm received an intervention identical to
those in Arm 2, with the addition of financial incentives for
blood pressure monitoring. This arm was subdivided into 2
arms; participants were eligible to receive the same incentive
amounts but framed differently. In the instant reward subarm,
participants received SGD $3 (an exchange rate of
approximately SGD $1 to US $0.75 was applicable at the time
of publication) for each day they measured their blood pressure,
up to 3 times per week (SGD $9 if they measured their blood
pressure on at least 3 different days, SGD $6 if they measured
their blood pressure on at least 2 different days, SGD $3 if they
measured their blood pressure on at least 1 day, or no financial
incentive if they did not measure their blood pressure). In the
health capital subarm, participants received an initial health
capital of SGD $72. Participants’ health capital increased by
SGD $6 on each week they measured their blood pressure on
at least 3 different days. Participants’ health capital decreased
weekly by 10% per missing blood pressure reading. Health
capital decreased by 10% if the participant measured their blood
pressure on 2 different days, by 20% if the participant measures
their blood pressure only on 1 day, and by 30% if the participant
did not measure their blood pressure. Therefore, at the end of
the 24-week intervention, Arm 3 participants could receive
incentives up to SGD $216 for blood pressure monitoring.
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Noncontingent study payments (Multimedia Appendix 9) to
Arm 1 and 2 participants and incentive payments to Arm 3
participants (Multimedia Appendix 7, Table A7.4) in the form
of supermarket vouchers were disbursed by the clinical research
coordinator at the month 6 assessment.
Participant Withdrawal
During the study intervention, the clinical research coordinator
reviewed the participants’ medical records and contacted the
participants via phone to determine if there were any serious
adverse events, changes in medical condition, hospitalizations,
or referrals to specialist outpatient clinics that may require a
withdrawal from the study. The study doctor reviewed the
participant’s medical records and determined when there was
a need to do so. Participants who were newly diagnosed with a
hypertension related condition or complication or met the
following exclusion criteria: clinically unstable heart failure,
acute kidney injury, glomerulonephritis, liver disease, atrial
fibrillation, prescribed warfarin or anti-coagulants, double
mastectomy, pregnant, epoxy-resin allergy, referred to specialist
outpatient clinic, or hospitalized for complications were
withdrawn. Those who had a progression of an existing
condition (eg, impaired kidney function) could remain in the
study. For study participants who were withdrawn by the study
team, a payment of SGD $80 in compensation for forgoing
potential payments that the participant might have received had
they remained in the study was given. Participants were free to
withdraw their consent and discontinue their participation at
any time during the intervention, without prejudice or effect on
their medical care; however, all data collected until the time of
the participants’ withdrawal were kept to allow for a
comprehensive evaluation.
Outcome Measures
The outcome measures and schedule of collection can be found
in Multimedia Appendix 10.
Primary Outcome
The primary outcome was the mean reduction in systolic blood
pressure in 6 months. This was to be obtained from the
participants’month 6 ambulatory blood pressure monitor results.
systolic blood pressure is associated with increased risk of
cardiovascular disease [45-47].
Secondary Outcomes
Secondary outcomes were mean reduction in diastolic blood
pressure in 6 months, obtained from the participants’ month 6
ambulatory blood pressure monitor results; mean cost of
financial incentives at month 6, calculated as the total financial
incentives earned by Arm 3 participants at the end of the
intervention and to be used as part of the cost-effectiveness
analysis; mean time taken for the intervention at month 6,
calculated as the total number of minutes spent by the clinical
research coordinator intervening for the colored flags, adherence
calculation, and payment of financial incentives for all study
arm participants during the month 6 assessment and to be used
as part of the cost-effectiveness analysis; mean adherence to
home blood pressure monitoring at month 6; effectiveness of
the framing of financial incentives in decreasing nonadherence
to blood pressure self-monitoring; and mean adherence to
antihypertensive medication (prescribed to be taken most
frequently) at month 6.
Diastolic blood pressure may have some associations with future
systolic hypertension and with increased risk of cardiovascular
disease [47-51].
Exploratory Outcomes
Exploratory outcomes were the proportion of participants who
have target blood pressure (defined as less than 130 mmHg/80
mmHg) at month 6; mean change from baseline in European
Quality of Life-5 Dimensions-5 Levels [52] score at month 6;
mean change from baseline in Brief Illness Perception
Questionnaire [53] score, which assesses perceptions of
hypertension, at month 6; mean change from baseline in the
Global Physical Activity Questionnaire at month 6; mean change
from baseline in the Dietary Practices Questionnaires [54] at
month 6; mean change from baseline in Healthcare Services
Expenditure at month 6; and the Treatment Satisfaction on home
blood pressure monitoring, which is a modified version of the
Treatment Satisfaction Questionnaire for Medication [55], at
month 6.
Sample Size
A key parameter is the systolic blood pressure. To assess this,
we computed the sample size to be able to detect differences of
10 mmHg in average systolic blood pressure between study
arms at the 5% level with 80% power. To compute the overall
sample size, we computed the size of the intervention groups
that is required for testing for difference between intervention
groups (study arms 2 and 3). After applying a Bonferroni
correction (by dividing the test’s significance level by 2, which
is the number of comparisons that we test in our study for the
primary outcome), we found that 68 patients per intervention
group is necessary to detect mean differences in systolic blood
pressure of 10 mmHg (with 2.5% significance level and 80%
power). Given the resulting cumulated sample size for the 2
intervention arms of 136, we then computed the size required
for the control group to test the overall effect of the wireless
home blood pressure monitoring (with and without financial
incentives) with the same effect size, significance level, and
power. This computation yielded a size of 45 for the control
group. After accounting for 25% attrition in each arm, the
resulting sample sizes were 56 for the control group and 84 for
each intervention group, resulting in a total of 224 patients. We
assumed throughout that the standard deviation of systolic blood
pressure is 19 (which is slightly greater than the maximum value
reported by a similar size 6-month study of patients with
uncontrolled hypertension [56]).
Randomization
Participants were allocated to 1 of 3 study arms by random
assignment. Prior to recruitment, randomization numbers was
generated by the principal investigator using Stata software
(StataCorp LLC) to create an assignment schedule for
block-randomization to allocate eligible participants into 1 of
the 3 study arms in a ratio of 2:3:3. Randomized stratification
was based on whether the patient had diabetes and study site.
The block size was not communicated to SingHealth Polyclinics
to minimize the predictability of the random sequence.
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Furthermore, in order to test a secondary hypothesis (H5), the
patients in the home blood pressure monitoring with financial
incentives arm were further randomly divided into 2 equal-size
groups, 1 per incentive type. The project coordinator and
principal investigator then stored the assignment schedule on a
secure server at Duke–NUS Medical School. For allocation
concealment, the project coordinator and a Duke–NUS Medical
School staff external to the study team enclosed the assignments
in sequentially numbered, opaque, sealed randomization
envelopes. These were handed over to the clinical research
coordinator for participant enrollment and assignment.
Allocation Blinding
The clinical research coordinators were not blinded to the group
allocation during the study intervention as there was a need for
the clinical research coordinators to know the participants’arms
to assign study devices to the participants and carry out the
intervention accordingly and disburse payouts for the incentive
arm participants (Arm 3). The site investigators were also not
blinded as they had to explain the remote titration action plan
and advise on intervention for the colored protocols (Arm 2 and
3).
Data Management and Monitoring
To maintain confidentiality, all enrolled participants were issued
a unique ID based on their randomization number and were
referred to via their unique ID thereon. Identifiable data were
kept at locked cabinets at Bedok and Marine Parade Polyclinics
and only accessible by the SingHealth Polyclinics team. Only
deidentified research data were passed to Duke–NUS Medical
School, and all data transfers were documented. All keyed in
deidentified research data were encrypted, password-protected
and stored on a secure server. Blood pressure readings and home
blood pressure monitoring adherence data from the mobile app
were transmitted automatically to the app via the application
programming interface daily. The app did not contain any
identifying information, was password protected, and only
authorized members of the Duke–NUS Medical School team
had access to the website via 2-factor authentication.
Investigators have access to the research data collected. All
hardcopy research data collected are archived for the next 10
years in compliance with NUS's research data management
policies. No Data and Safety Monitoring Board was used for
this trial as the study was deemed to be low risk by the
investigators as this intervention was modelled after an existing
standard of care by the Polyclinics and not involving more than
minimal risk to the participants. Compensation was to be
considered on a case-by-case basis for unexpected injuries due
to nonnegligent causes. This trial was subjected to study review
visits and audits to ensure that all investigator-initiated research
is conducted effectively and efficiently.
Ethics
This study was approved by the SingHealth Centralised
Institutional Review Board E (2016/2026). Amendments to the
protocol or other study-related documents were approved by
the institutional review board.
Data Analysis
All main analyses were to be based on intent to treat. The mean
difference in the systolic blood pressure at 6 months was to be
assessed in the context of a linear mixed-effects model with a
random effect for subject and fixed effects for baseline mean
(the same in both arms) and change in mean at 6 months for
each treatment arm (one for each arm). The mixed-effects model
allows nonmissing data to be used in analysis without
imputation. For estimates of the treatment arm effects to be
unbiased, data must be missing-at-random. However, it is
possible that the analysis of the pattern of attrition would
indicate that additional covariates needed to be included in the
mixed-effects models. If data are not normally distributed,
appropriate transformations will be attempted before resorting
to using nonparametric statistical analysis methods.
Results
Recruitment at Bedok Polyclinic began on January 24, 2018
and at Marine Parade Polyclinic on June 26, 2018. From January
24, 2018 to July 10, 2018, 42 participants (18.75% of the total
sample size) were enrolled, and 33 participants completed the
6-month assessment by January 31, 2019. A decision was made
to terminate the study prematurely due to unforeseen delays
and resulting funding issues. No analysis was carried out due
to the lack of sample size and therefore no results are available.
Discussion
This paper reports a protocol for a randomized trial to determine
whether a wireless home blood pressure monitoring system,
with or without financial incentives, is more effective at
reducing blood pressure than a nonwireless home blood pressure
monitoring that relies on patient self-report or best practices.
While the 6-month study intervention is sufficient to detect
potential blood pressure improvement that is clinically
significant, a longer period would be needed to test for the
long-term effectiveness of the intervention. There is currently
no prior intervention that has the same components as those in
our wireless home blood pressure monitoring system.
Unfortunately, due to unforeseen events the study was stopped
prematurely. Regardless, as this study raises an interesting set
of research questions, this protocol may be of value to other
researchers considering similar efforts for blood pressure control
or other behavioral targets. Results of such a study would
provide evidence on whether a telemonitoring system with or
without financial incentives can improve hypertension
management, thereby reducing long-term complications and
health care cost. By interacting socioeconomic characteristics
with the intervention effect, this study may also have provided
evidence on the benefit incidence of interventions involving
financial incentives. The framing of financial incentives as
reward versus health capital, would also have informed the
design of future incentive strategies in hypertension management
and other chronic diseases. The study would also have added
to telemonitoring knowledge on hypertension self-management
in patients and remote clinical management of hypertension,
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which is increasingly relevant in light of COVID-19 and an increase in the use of telehealth in managing chronic diseases.
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